Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CCNC | P24863 | 7/20 | 0.43 |
| ▸ | CDK8 | P49336 | 7/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | MYLK | Q15746 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | CILK1 | Q9UPZ9 | 1/20 | 0.40 |
| ▸ | CDK11A | Q9UQ88 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25170515 | 0.85 | KCNH2 (0.45) | KCNH2CCNCCDK8FLT3MYLK | |
| SCHEMBL21662459 | 0.82 | KCNH2 (0.49) | KCNH2CCNCCDK8FLT3MYLK | |
| SCHEMBL1140333 | 0.82 | ALDH1A1 (0.46) | HPGDSYKMEN1KMT2A | |
| SCHEMBL22642936 | 0.80 | KCNH2 (0.53) | KCNH2CTSKCTSCNAMPT | |
| SCHEMBL26929522 | 0.80 | CCNC (0.60) | KCNH2CCNCCDK8FLT3MYLK | |
| SCHEMBL19155220 | 0.79 | CTSK (0.53) | KCNH2SYKCTSKCTSCNAMPT | |
| SCHEMBL13117201 | 0.78 | SYK (0.44) | CCNCCDK8SYKCTSKCTSC | |
| SCHEMBL19656294 | 0.77 | FFAR1 (0.43) | CCNCCDK8SYKFLT3MYLK | |
| SCHEMBL16100863 | 0.75 | KCNH2 (0.55) | KCNH2 | |
| SCHEMBL19656317 | 0.74 | CCNC (0.45) | CCNCCDK8HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840531-B2 | CDK8/19 inhibitors | JOINT STOCK COMPANY "BIOCAD" (RU) | 2023-12-12 | — | — | US | disclosed |
| US-11840531-B2 | CDK8/19 inhibitors | JOINT STOCK COMPANY "BIOCAD" (RU) | 2023-12-12 | — | — | US | disclosed |
| US-20210246138-A1 | CDK8/19 INHIBITORS | JOINT STOCK COMPANY "BIOCAD" (RU) | 2021-08-12 | — | — | US | disclosed |
| EP-3831829-A1 | CDK8/19 INHIBITORS | Joint Stock Company "Biocad" (RU) | 2021-06-09 | — | — | EP | disclosed |
| EP-3464267-B1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2020-09-23 | — | — | EP | disclosed |
| WO-2020027704-A1 | CDK8/19 INHIBITORS | ЗАКРЫТОЕ АКЦИОНЕРНОЕ ОБЩЕСТВО "БИОКАД" | 2020-02-06 | — | — | WO | disclosed |
| WO-2017202719-A1 | NEW PHENYLPYRAZOLYLACETAMIDE COMPOUNDS AND DERIVATIVES AS CDK8/CDK19 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840531-B2 | CDK8/19 inhibitors | CDK8, CDK9, CDK18 | KCNH2 4298/4885CCNC 35/4885CDK8 1/4885 |
| US-20210246138-A1 | CDK8/19 INHIBITORS | CDK8, CDK9, CDK18 | KCNH2 4298/4885CCNC 35/4885CDK8 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.